iLeukon Therapeutics Unveils Promising Phase I Findings for ILKN421H at SITC 2025 iLeukon Therapeutics presents encouraging Phase I trial data for ILKN421H, showcasing its potential in treating advanced solid tumors at the SITC 2025 conference.

iLeukon Therapeutics Unveils Promising Phase I Findings for ILKN421H at SITC 2025 #United_States #San_Diego #mRNA_Therapy #iLeukon_Therapeutics #ILKN421H

iLeukon Secures FDA Clearance for Phase II mRNA Cancer Trial iLeukon Therapeutics has received FDA approval for a Phase II trial of ILKN421H, an mRNA immunotherapy for advanced non-small cell lung cancer, showcasing impressive efficacy.

iLeukon Secures FDA Clearance for Phase II mRNA Cancer Trial #United_States #San_Diego #mRNA_Therapy #iLeukon_Therapeutics #ILKN421H